Inhibition of platelet activation by peptide analogs of the β3-intracellular domain of platelet integrin αiIbβ3 conjugated to the cell-penetrating peptide Tat(4860)

Platelets

Volumn 20, Issue 8, 2009, Pages 539-547

  Dimitriou, Andromaxi A ^a   Stathopoulos, Panagiotis ^a   Mitsios, John V ^a   Sakarellos Daitsiotis, Maria ^a   Goudevenos, John ^b   Tsikaris, Vassilios ^a   Tselepis, Alexandros D ^a  

^a UNIVERSITY OF IOANNINA   (Greece)

^b UNIVERSITY OF IOANNINA   (Greece)

Author keywords

3 cytoplasmic domain; IIb 3 receptor; Cell penetrating conjugates; Platelet activation inhibitors; Tat conjugated peptides

Indexed keywords

ALPHAIIBBETA3 INTEGRIN; CARBOXYFLUORESCEIN; CELL PENETRATING PEPTIDE; DUAL SPECIFICITY PHOSPHATASE 2; FIBRINOGEN; INTEGRIN; PADGEM PROTEIN; PEPTIDE DERIVATIVE; PROTEIN TAT[48-60]; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; ARTICLE; CELL MEMBRANE PERMEABILITY; CONFOCAL LASER MICROSCOPY; CONJUGATE; CONJUGATION; CONTROLLED STUDY; HUMAN; HUMAN CELL; PEPTIDE SYNTHESIS; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN MOTIF; PROTEIN SECRETION; SCANNING ELECTRON MICROSCOPY; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; THROMBOCYTE MEMBRANE;

AMINO ACID SEQUENCE; ANIMALS; BLOOD PLATELETS; CELL LINE; DOSE-RESPONSE RELATIONSHIP, DRUG; FIBRINOGEN; HUMANS; MOLECULAR SEQUENCE DATA; P-SELECTIN; PEPTIDE FRAGMENTS; PEPTIDES; PLATELET ACTIVATION; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; SIGNAL TRANSDUCTION; TAT GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS;

EID: 73649148682     PISSN: 09537104     EISSN: 13691635     Source Type: Journal    
DOI: 10.3109/09537100903324219     Document Type: Article

References (37)

1. Hynes RO. Integrins: A family of cell surface receptors. Cell 1987;48:549-554.
2. Hynes RO. Integrins: Versatility, modulation, and signaling in cell adhesion. Cell 1992;69:11-25.
3. Shattil SJ, Kashiwagi H, Pampori N. Integrin signaling: The platelet paradigm. Blood 1998;91:2645-2657.
4. Litjens PE, Akkerman JW, Van Willigen G. Platelet integrin alphaIIbbeta3: Target and generator of signalling. Platelets 2000;11:310-319.
5. Dedhar S, Hannigan GE. Integrin cytoplasmic interactions and bidirectional transmembrane signalling. Curr Opin Cell Biol 1996;8:657-669.
6. Shattil SJ. Signaling through platelet integrin alpha IIb beta 3: Inside-out, outside-in, and sideways. Thromb Haemost 1999;82:318-325.
7. Biris N, Abatzis M, Mitsios JV, Sakarellos-Daitsiotis M, Sakarellos C, Tsoukatos D, Tselepis AD, Michalis L, Sideris D, Konidou G, et al. Mapping the binding domains of the alpha(IIb) subunit. A study performed on the activated form of the platelet integrin alpha(IIb)beta(3). Eur J Biochem 2003;270:3760-3767.
8. Mitsios JV, Tambaki AP, Abatzis M, Biris N, Sakarellos-Daitsiotis M, Sakarellos C, Soteriadou K, Goudevenos J, Elisaf M, Tsoukatos D, et al. Effect of synthetic peptides corresponding to residues 313-332 of the alphaIIb subunit on platelet activation and fibrinogen binding to alphaIIbbeta3. Eur J Biochem 2004;271:855-862.
9. Mitsios JV, Stamos G, Rodis FI, Tsironis LD, Stanica MR, Sakarellos C, Tsoukatos D, Tsikaris V, Tselepis AD. Investigation of the role of adjacent amino acids to the 313- 320 sequence of the alphaIIb subunit on platelet activation and fibrinogen binding to alphaIIbbeta3. Platelets 2006;17: 277-282.
10. Stanica R, Benaki D, Rodis FI, Mikros E, Tsoukatos D, Tselepis A, Tsikaris V. Structure-activity relationships of alphaIIb 313-320 derived peptide inhibitors of human platelet aggregation. J Pept Sci 2008;14:1195-1202.
11. Tsikaris V. The anti-platelet approach targeting the fibrinogen ligand of the GPIIB/IIIa receptor. J Pept Sci 2004; 10:589-602.
12. Vinogradova O, Velyvis A, Velyviene A, Hu B, Haas T, Plow E, Qin J. A structural mechanism of integrin alpha(IIb)beta(3) ''inside-out'' activation as regulated by its cytoplasmic face. Cell 2002;110:587-597.
13. Koloka V, Christofidou ED, Vaxevanelis S, Dimitriou AA, Tsikaris V, Tselepis AD, Panou-Pomonis E, Sakarellos-Daitsiotis M, Tsoukatos DC. A palmitoylated peptide, derived from the acidic carboxyl-terminal segment of the integrin alphaIIb cytoplasmic domain, inhibits platelet activation. Platelets 2008;19:502-511.
14. Liu S, Calderwood DA, Ginsberg MH. Integrin cytoplasmic domain-binding proteins. J Cell Sci 2000;113:3563-3571.
15. Zhao R, Pathak AS, Stouffer GA. beta(3)-Integrin cytoplasmic binding proteins. Arch Immunol Ther Exp (Warsz) 2004;52:348-355.
16. Xi X, Bodnar RJ, Li Z, Lam SC, Du X. Critical roles for the COOH-terminal NITY and RGT sequences of the integrin beta3 cytoplasmic domain in inside-out and outside-in signaling. J Cell Biol 2003;162:329-339.
17. Calderwood DA, Zent R, Grant R, Rees DJ, Hynes RO, Ginsberg MH. The Talin head domain binds to integrin beta subunit cytoplasmic tails and regulates integrin activation. J Biol Chem 1999;274:28071-28074.
18. Calderwood DA, Yan B, De Pereda JM, Alvarez BG, Fujioka Y, Liddington RC, Ginsberg MH. The phosphotyrosine binding-like domain of talin activates integrins. J Biol Chem 2002;277:21749-21758.
19. Eigenthaler M, Ho?fferer L, Shattil SJ, Ginsberg MH. A conserved sequence motif in the integrin beta3 cytoplasmic domain is required for its specific interaction with beta3- endonexin. J Biol Chem 1997;272:7693-7698.
20. Kashiwagi H, Schwartz MA, Eigenthaler M, Davis KA, Ginsberg MH, Shattil SJ. Affinity modulation of platelet integrin alphaIIbbeta3 by beta3-endonexin, a selective binding partner of the beta3 integrin cytoplasmic tail. J Cell Biol 1997;137:1433-1443.
21. Bodansky M, Bodansky A. The practice of peptide synthesis. 2nd ed. Berlin: Springer; 1994.
22. Goodman M, Felix A, Moroder L, Toniolo G, ed. Methods of organic chemistry: Synthesis of peptide and peptidomimetics. Stuttgard: Thieme, 2003.
23. Papas S, Akoumianaki T, Kalogiros C, Hadjiarapoglou L, Theodoropoulos PA, Tsikaris V. Synthesis and antitumor activity of peptide-paclitaxel conjugates. J Pept Sci 2007; 13:662-671.
24. Tsironis LD, Mitsios JV, Milionis HJ, Elisaf M, Tselepis AD. Effect of lipoprotein (a) on platelet activation induced by platelet-activating factor: Role of apolipoprotein (a) and endogenous PAF-acetylhydrolase. Cardiovasc Res 2004; 63:130-138.
25. Di?z-Ricart M, Arderiu G, Estebanell E, Pe?ez-Pujol S, Lozano M, White JG, Escolar G, Ordinas A. Inhibition of cytoskeletal assembly by cytochalasin B prevents signaling through tyrosine phosphorylation and secretion triggered by collagen but not by thrombin. Am J Pathol 2002; 160:329-337.
26. Vivès E, Brodin P, Lebleu B. A truncated HIV-1 Tat protein basic domain rapidly translocates through the plasma membrane and accumulates in the cell nucleus. J Biol Chem 1997;272:16010-16017.
27. Futaki S, Suzuki T, Ohashi W, Yagami T, Tanaka S, Ueda K, Sugiura Y. Arginine-rich peptides. An abundant source of membrane-permeable peptides having potential as carriers for intracellular protein delivery. J Biol Chem 2001;276: 5836-5840.
28. Futaki S, Goto S, Sugiura Y. Membrane permeability commonly shared among arginine-rich peptides. J Mol Recognit 2003;16:260-264.
29. Derossi D, Calvet S, Trembleau A, Brunissen A, Chassaing G, Prochiantz A. Cell internalization of the third helix of the Antennapedia homeodomain is receptorindependent. J Biol Chem 1996;271:18188-18193.
30. Richard JP, Melikov K, Vives E, Ramos C, Verbeure B, Gait MJ, Chernomordik LV, Lebleu B. Cell-penetrating peptides. A reevaluation of the mechanism of cellular uptake. J Biol Chem 2003;278:585-590.
31. Martin KMG, Moran N, Shields DC, Kenny D. A palmitylated peptide derived from the glycoprotein Ib beta cytoplasmic tail inhibits platelet activation. J Thromb Haemost 2003;1:2643-2652.
32. Jie C, Ling Yu, Liping Wang, Xuexun Fang, Li Li, Wei Li. Stability of Synthetic Exendin-4 in Human Plasma In Vitro. Protein & Peptide Letters 2007;14:19-25.
33. Papamichael N, Stathopoulou EM, Roussa VD, Tsironis LD, Kotsia AP, Stanica RM, Moussis V, Tsikaris V, Katsouras CS, Tselepis AD, et al. Effect of a synthetic peptide corresponding to residues 313 to 320 of the alphaIIb subunit of the human platelet integrin alphaIIbbeta3 on carotid artery thrombosis in rabbits. J Pharmacol Exp Ther 2009;329: 634-640.
34. Brinckerhoff L, Kalasnikov VV, Thompson LW, Yamshchikov GV, Pierce RA, Galavotti HS, Engelhard VH, Slinglff CL. Terminal modifications inhibit proteolytic degradation of an immunogenic MART-127-35 peptide: Implications for peptide vaccines. Int J Cancer 1999;83: 326-334.
35. Hers I, Donath J, Litjens PE, Van Willigen G, Akkerman JW. Inhibition of platelet integrin alpha(IIb)beta(3) by peptides that interfere with protein kinases and the beta(3) tail. Arterioscler Thromb Vasc Biol 2000;20:1651-1660.
36. Liu KY, Timmons S, Lin YZ, Hawiger J. Identification of a functionally important sequence in the cytoplasmic tail of integrin beta 3 by using cell-permeable peptide analogs. Proc Natl Acad Sci USA 1996;93:11819-11824.
37. Litjens PE, Kroner CI, Akkerman JW, Van Willigen G. Cytoplasmic regions of the beta3 subunit of integrin alphaIIbbeta3 involved in platelet adhesion on fibrinogen under flow conditions. J Thromb Haemost 2003;1: 2014-2021.